Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Marin

Showing results (121-130 of 180) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|March 30, 2021
Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host DiseaseRohtesh S Mehta, Rima M Saliba, Anna Jan, et al.
Transplantation and Cellular Therapy|May 23, 2021
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid LeukemiaFevzi F Yalniz, Rima M Saliba, Uri Greenbaum, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Blood|March 30, 2017
Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantationLohith S Bachegowda, Rima M Saliba, Reshma Ramlal, et al.
Haematologica|August 8, 2015
Better allele-level matching improves transplant-related mortality after double cord blood transplantationBetül Oran, Kai Cao, Rima M Saliba, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
Pageof 18

Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|March 30, 2021
Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host DiseaseRohtesh S Mehta, Rima M Saliba, Anna Jan, et al.
Transplantation and Cellular Therapy|May 23, 2021
Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid LeukemiaFevzi F Yalniz, Rima M Saliba, Uri Greenbaum, et al.
The New England Journal of Medicine|August 16, 2002
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor betaJane F Apperley, Martine Gardembas, Junia V Melo, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
JAMA Oncology|September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical TrialElias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Blood|May 31, 2013
Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalingHugues de Lavallade, Ahmad Khoder, Melanie Hart, et al.
Blood|March 30, 2017
Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantationLohith S Bachegowda, Rima M Saliba, Reshma Ramlal, et al.
Haematologica|August 8, 2015
Better allele-level matching improves transplant-related mortality after double cord blood transplantationBetül Oran, Kai Cao, Rima M Saliba, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 7, 2016
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study ResultsPartow Kebriaei, Roland Bassett, Genevieve Lyons, et al.
Pageof 18